Matthias Gehringer

List of Publications by Year in Descending Order

31 papers	731 citations	14 h-index	27 g-index
41 ext. papers	982 ext. citations	5.6 avg, IF	5.04 L-index

#	Paper	IF	Citations
31	Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer.. *Journal of Medicinal Chemistry*, **2022**, 65, 4616-4632	8.3	0
30	An Antigen Capture Assay for the Detection of Mycolactone, the Polyketide Toxin of. *Journal of Immunology*, **2021**, 206, 2753-2762	5.3	1
29	Current jakinibs for the treatment of rheumatoid arthritis: a systematic review. *Inflammopharmacology*, **2021**, 29, 595-615	5.1	5
28	Nocathioamides, Uncovered by a Tunable Metabologenomic Approach, Define a Novel Class of Chimeric Lanthipeptides. *Angewandte Chemie - International Edition*, **2021**, 60, 16472-16479	16.4	2
27	N-(6-Chloro-3-nitropyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)isoquinolin-3-amine. *MolBank*, **2021**, 2021, M1181	0.5	0
26	Chemical Probes for Understudied Kinases: Challenges and Opportunities. *Journal of Medicinal Chemistry*, **2021**,	8.3	1
25	Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	6
24	Covalent Kinase Inhibitors: An Overview. *Topics in Medicinal Chemistry*, **2020**, 43-94	0.4	3
23	Development of an ELISA for the quantification of mycolactone, the cytotoxic macrolide toxin of Mycobacterium ulcerans. *PLoS Neglected Tropical Diseases*, **2020**, 14, e0008357	4.8	5
22	Covalent Janus Kinase 3 Inhibitors. *Topics in Medicinal Chemistry*, **2020**, 225-256	0.4	1
21	Configurationally Stabilized Analogs of Exotoxins Mycolactones A and B Reveal the Importance of Side Chain Geometry for Mycolactone Virulence. *Organic Letters*, **2019**, 21, 5853-5857	6.2	5
20	Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. *Journal of Medicinal Chemistry*, **2019**, 62, 5673-5724	8.3	218
19	Developing Small-Molecule Inhibitors of HECT-Type Ubiquitin Ligases for Therapeutic Applications: Challenges and Opportunities. *ChemBioChem*, **2018**, 19, 2123-2135	3.8	21
18	Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold. *Journal of Medicinal Chemistry*, **2018**, 61, 5350-5366	8.3	27
17	The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. *ACS Chemical Biology*, **2017**, 12, 1297-1307	4.9	52
16	Click Chemistry: Novel Applications in Cell Biology and Drug Discovery. *Angewandte Chemie - International Edition*, **2017**, 56, 15504-15505	16.4	22
15	Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4229-4237	2.9	23

14	The chemistry and biology of mycolactones. *Beilstein Journal of Organic Chemistry*, **2017**, 13, 1596-1660	2.5	23
13	Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1). *Future Medicinal Chemistry*, **2016**, 8, 1537-51	4.1	6
12	Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket. *Cell Chemical Biology*, **2016**, 23, 1335-1340	8.2	62
11	New insights into novel inhibitors against deoxyhypusine hydroxylase from plasmodium falciparum: compounds with an iron chelating potential. *Amino Acids*, **2015**, 47, 1155-66	3.5	9
10	Inhibitors of c-Jun N-terminal kinases: an update. *Journal of Medicinal Chemistry*, **2015**, 58, 72-95	8.3	63
9	Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition. *ACS Combinatorial Science*, **2015**, 17, 5-10	3.9	14
8	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014). *Expert Opinion on Therapeutic Patents*, **2015**, 25, 849-72	6.8	39
7	A direct enzyme-linked immunosorbent assay (ELISA) for the quantitative evaluation of Janus Kinase 3 (JAK3) inhibitors. *Analytical Methods*, **2014**, 6, 8817-8822	3.2	11
6	Metabolism of a novel skepinone L-like p38 mitogen-activated protein kinase inhibitor. *MedChemComm*, **2014**, 5, 808	5	
5	Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes. *ChemMedChem*, **2014**, 9, 277-81	3.7	29
4	Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres. *ChemMedChem*, **2014**, 9, 2516-27	3.7	25
3	2-(3-{(3R,4R)-4-Methyl-3-[meth-yl(7H-pyrrolo-[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl}oxetan-3-yl)aceto-nitrile monohydrate. *Acta Crystallographica Section E: Structure Reports Online*, **2014**, 70, o382-3		
2	tert-Butyl N-[(3R,4R)-1-(2-cyano-acet-yl)-4-methyl-piperidin-3-yl]-N-methyl-carbamate. *Acta Crystallographica Section E: Structure Reports Online*, **2013**, 69, o935		
1	Silica-supported l-proline organocatalysts for asymmetric aldolisation. *Tetrahedron: Asymmetry*, **2009**, 20, 2880-2885		44